Hendrik Peter Scholl - 21 Apr 2026 Form 4 Insider Report for BELITE BIO, INC (BLTE)

Reporting relationship: Chief Medical Officer
Issuer ticker: BLTE
Reported as of: 21 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Apr 2026, 16:20:10 UTC
Prior SEC filing: 18 Mar 2026
Next SEC filing: 17 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Hendrick Peter Scholl

Key filing fact

Hendrik Peter Scholl filed Form 4 for BELITE BIO, INC (BLTE) on 23 Apr 2026.

Key facts

This page summarizes Hendrik Peter Scholl's Form 4 filing for BELITE BIO, INC (BLTE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Apr 2026, 16:20.

Change

Previous filing in this sequence was filed on 18 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002113223 Primary reporting owner

Scholl Hendrik Peter

Relationship: Chief Medical Officer
Address: GOTTHARDSTRASSE 26, ZUG, SWITZERLAND
Signature: /s/ Hendrick Peter Scholl
Signature date: 23 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLTE transaction Derivative

Stock Option (right to buy)

Other

Transaction value
Shares: +10,000
Change %
Price: $0.000000^*
Shares after: 10,000
Date: 21 Apr 2026
Ownership: By Bioptima Ltd.
Underlying class: Ordinary Shares
Underlying amount: 10,000
Exercise price: $77.40
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On October 7, 2025, the reporting person was granted an option which shall vest upon satisfaction of certain performance criteria. Such performance criteria was met on 04/21/2026, resulting in vesting of the option as to 10,000 ordinary shares.